Taysha Gene Therapies (TSHA) Construction in Progress (2021 - 2022)
Taysha Gene Therapies' (TSHA) quarterly Construction in Progress came in at $59.0 million in Q3 2022, up 160662.94% year-on-year from N/an in Q3 2021, and up 4.8% quarter-over-quarter from $56.3 million in Q2 2022.
Taysha Gene Therapies (TSHA) Construction in Progress (2021 - 2022) Analysis & Trends
Taysha Gene Therapies has disclosed Construction in Progress across 2 years of filings, most recently posting $59.0 million for Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 59.00 Mn |
| Jun 30, 2022 | 56.30 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Sep 30, 2021 | 36,700.00 |
| Jun 30, 2021 | 30.30 Mn |